Company Overview of Nile Therapeutics, Inc
As of November 20, 2013, Nile Therapeutics, Inc was acquired by Capricor, Inc. Nile Therapeutics, Inc., a development stage biopharmaceutical company, develops pharmaceutical products for the treatment of cardiovascular and renal diseases. Its lead product candidate include Cenderitide, a chimeric natriuretic peptide that has completed Phase I clinical trial for the treatment of patients following admission for acutely decompensated heart failure. The company also develops CU-NP, a natriuretic peptide, which is in pre-clinical studies for the treatment of cardiovascular and renal diseases. Nile Therapeutics, Inc. was founded in 2005 and is based in San Mateo, California.
63 Bovet Road
San Mateo, CA 94402
Founded in 2005
Key Executives for Nile Therapeutics, Inc
Nile Therapeutics, Inc does not have any Key Executives recorded.
Nile Therapeutics, Inc Key Developments
Similar Private Companies By Industry
|Kytogenics Pharmaceutical, Inc.||United States|
|Gilead Colorado, Inc.||United States|
|Nanomedical Systems, Inc.||United States|
|Gentis, Inc.||United States|
|Molecular Templates, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Nile Therapeutics, Inc, please visit www.nilethera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.